Mesoblast (MESO) Non-Current Assets (2015 - 2025)
Mesoblast's (MESO) quarterly Non-Current Assets came in at $579.8 million in Q4 2025, down 0.65% year-on-year from $583.6 million in Q4 2024, and little changed quarter-over-quarter from $580.3 million in Q2 2025.
Mesoblast (MESO) Non-Current Assets (2015 - 2025) Analysis & Trends
Mesoblast has disclosed Non-Current Assets across 11 years of filings, most recently posting $579.8 million for Q4 2025.
- Non-Current Assets for Q4 2025 came in at $579.8 million, down 0.65% year-over-year; the trailing twelve-month figure through Dec 2025 was $579.8 million (down 0.65% YoY), and the FY2025 annual result was $580.3 million, changed 0.4% from the prior year.
- Non-Current Assets came in at $579.8 million for Q4 2025 at Mesoblast, roughly flat from $580.3 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $596.5 million in Q2 2021 to a low of $579.8 million in Q4 2025.
- The 5-year median for Non-Current Assets is $589.9 million (2022), against an average of $589.3 million.
- Across the five-year window, Non-Current Assets dropped 0.01% in 2021 and fell 0.96% in 2022, its largest moves.
- Mesoblast's Non-Current Assets stood at $595.6 million in 2021, then dropped by 0.96% to $589.9 million in 2022, then dropped by 0.81% to $585.1 million in 2023, then decreased by 0.25% to $583.6 million in 2024, then slipped by 0.65% to $579.8 million in 2025.
- The last three Non-Current Assets figures came in at $579.8 million (Q4 2025), $580.3 million (Q2 2025), and $583.6 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Mesoblast | 21.68 Bn | 21.55 Bn | - | 579.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 579.82 Mn |
| Jun 30, 2025 | 580.33 Mn |
| Dec 31, 2024 | 583.64 Mn |
| Jun 30, 2024 | 582.69 Mn |
| Dec 31, 2023 | 585.13 Mn |
| Jun 30, 2023 | 587.76 Mn |
| Mar 31, 2023 | 589.08 Mn |
| Dec 31, 2022 | 589.93 Mn |
| Sep 30, 2022 | 591.54 Mn |
| Jun 30, 2022 | 592.31 Mn |
| Mar 31, 2022 | 593.56 Mn |
| Dec 31, 2021 | 595.64 Mn |
| Sep 30, 2021 | 595.60 Mn |
| Jun 30, 2021 | 596.49 Mn |
| Mar 31, 2021 | 596.36 Mn |
| Dec 31, 2020 | 596.85 Mn |
| Sep 30, 2020 | 596.84 Mn |
| Jun 30, 2020 | 597.05 Mn |
| Mar 31, 2020 | 596.40 Mn |
| Dec 31, 2019 | 596.93 Mn |